Xuanzhu Pharma Co. Ltd. has divulged cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of castration-resistant prostate cancer.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has identified compounds acting as diacylglycerol kinase ζ (DGK-ζ, DGKZ) inhibitors reported to be useful for the treatment of cancer.
Shanghai Meiyue Biotech Development Co. Ltd. has synthesized spiro compounds acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration, glomerulonephritis, atypical hemolytic uremic syndrome, membranous nephropathy, myasthenia gravis, paroxysmal nocturnal hemoglobinuria, diabetic retinopathy and rheumatoid arthritis, among others.
Genescience Pharmaceuticals Co. Ltd. has identified phosphatidylinositol 3-kinase α (PI3Kα) inhibitors, particularly PI3Kα (H1047R mutant), reported to be useful for the treatment of cancer and PIK3CA-related overgrowth spectrum.
Scientists at Atmosr SAS and Medetia SAS have synthesized adenine derivatives acting as heat shock protein 90 (HSP90) inhibitors reported to be useful for the treatment of cancer, neurodegenerative diseases, infections, myelofibrosis, acute pancreatitis, psoriasis and ROHHAD (rapid-onset obesity, hypothalamic dysfunction, hypoventilation, autonomic dysregulation).
Chengdu Zeling Biomedical Technology Co. Ltd. has disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammatory, autoimmune, cardiovascular, renal, gastrointestinal, respiratory and neurological disorders.
Genetic Intelligence Inc. has described compounds acting as IL-2 expression or activity modulators reported to be useful for the treatment of cancer, infections, autoimmune diseases and inflammatory disorders.
RSS